BioSpace News Archive

Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today hosted a Key Opinion Leader (KOL) webinar and provided an update on the Company’s ongoing Phase 3 program evaluating once-daily Diazoxide Choline Controlled Release (DCCR) tablets for the treatment of Prader-Willi Syndrome (PWS).

Angion Biomedica Corp. (Angion) (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced the pricing of its initial public offering on February 4, 2021 of 5,000,000 shares of common stock at a public offering price of $16.00 per share, for gross proceeds of $80,000,000 million,

Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced the election of Robert Postma to its Board of Directors (the “Board”), effective immediately. Mr. Postma is the Founder of WaterMill Asset Management, a sizeable and long-term shareholder of Ziopharm.

The National Kidney Foundation is proud to announce the launch of its first-ever Health Equity Advisory Committee responsible for directing and championing NKF’s health equity, community health, and social justice efforts through research, education and key partnerships.

The Galien Foundation announced today an upcoming webinar series that will explore the critical role digital technologies play in today’s life sciences, specifically in clinical trials and the development of the COVID-19 vaccines.

SeqWell, a leader in genomic technologies, announced the release of its plexWell Single Cell Rapid Kit, simplifying and accelerating the preparation of NGS libraries for single-cell RNA sequencing.

InMed Pharmaceuticals Inc. today announced that it has entered into definitive agreements with certain institutional investors to raise aggregate gross proceeds of approximately US$4.5 million at a price of US$4.25 per unit in a private placement of its equity securities.

Itamar Medical Ltd. (“Itamar Medical” or the “Company”) (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders, today announced the pricing of its public offering of 3,049,130 American Depositary Shares (“ADSs”) at a public offering price of $22.75 per ADS.

EastWest Bioscience (the “Company” or “EastWest”) (TSXV:EAST) announces, subject to its stock option plan, the grant of 1,720,000 stock options to certain directors, officers, employees and consultants issued pursuant to the Company’s stock option plan.

Prevacus, Inc., a leading biopharmaceutical company focused on developing treatments for concussion (mild traumatic brain injury (mTBI)) and other neurological disorders; today announced that it has entered into a definitive agreement for the sale of drug candidate PRV-002 to Odyssey Group International (OTCQB:ODYY).